On October 7, 2019, Mylan Pharmaceuticals filed 2 Petitions for Inter Partes Review (IPR2019-01657 and IPR2019-01658) of U.S. Patent RE47,614, which is assigned to Sanofi-Aventis. The ’614 patent claims a configuration for securely holding a cartridge within a drug delivery device, which can be used to deliver insulin. The petitions both contend that all claims of the ’614 patent are invalid for obviousness. In the Explanation of Multiple Petitions, Mylan asserts that each petition represent a single ground of unpatentability and that the two petitions were required to comply with word-count constraints due to the number of claims (1-18).
The post Mylan files IPR petitions challenging a Sanofi drug-delivery device patent appeared first on Big Molecule Watch.